Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Titan BiotechBOM:524717 +3.11%51 Days Inventory is 270.27 as of Mar. 2026, which is 62% above its 10-year median of 167.21. GuruFocus rates BOM:524717 with a GF Score™ of 51/100 and a GF Value™ of ₹145.57 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 637 Biotechnology companies, Titan Biotech ranks worse than 52.9% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Titan Biotech's Average Total Inventories for the
three
months ended in Mar. 2026 was ₹558 Mil. Titan Biotech's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹188 Mil.
Hence, Titan Biotech's Days Inventory for the
three
months ended in Mar. 2026 was 270.27.
The historical rank and industry rank for Titan Biotech's Days Inventory or its related term are showing as below:
BOM:524717'
s Days Inventory Range Over the Past 10 Years
Min: 115.76 Med: 167.21 Max: 242.98
Current: 192.51
During the past 13 years, Titan Biotech's highest Days Inventory was 242.98. The lowest was 115.76. And the median was 167.21.
BOM:524717's Days Inventory is ranked worse than 52.9% of 637
companies
in the Biotechnology industry
Industry Median: 183.16
vs BOM:524717: 192.51
Titan Biotech's Days Inventory
declined
from Mar. 2025 (308.90) to Mar. 2026 (270.27).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Titan Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.34.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Titan Biotech's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.14.
Titan Biotech (BOM:524717) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Titan Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Titan Biotech's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Titan Biotech Days Inventory Related Terms
Titan Biotech Days Inventory Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Titan Biotech's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Days Inventory distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a Days Inventory of 270.27 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Titan Biotech and its competitors. This is 62% above median its historical median of 167.21. Over the past decade, Titan Biotech's Days Inventory has ranged from 115.76 to 242.98. According to the industry distribution chart, Titan Biotech ranks #337 out of 637 companies in the Biotechnology industry, placing it in the top 52.9%.
Is Titan Biotech's Days Inventory too high?
Titan Biotech's current Days Inventory of 270.27 is 62% above median its 10-year median of 167.21. Over the past 10 years, this metric has ranged from a low of 115.76 to a high of 242.98. The Biotechnology industry median Days Inventory is 183.16. Titan Biotech's value of 270.27 is 47.6% above this industry median. Based on the distribution chart, Titan Biotech ranks #337 out of 637 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #337 out of 637 companies for Days Inventory. This places Titan Biotech in the lower half of its industry. The industry median Days Inventory is 183.16. Titan Biotech's value of 270.27 is 47.6% above this benchmark. Historically, Titan Biotech's own Days Inventory has ranged from 115.76 to 242.98 over the past decade. While the company's 10-year median is 167.21 vs. the industry median of 183.16, Titan Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.16, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Titan Biotech's current Days Inventory of 270.27 is 47.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Titan Biotech and its competitors. For the Biotechnology industry, the median Days Inventory is 183.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Titan Biotech's current Days Inventory is 270.27, which is 62% above median its own 10-year median of 167.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹145.57, compared to a current price of ₹427.80 — trading 193.9% above its estimated fair value. The current Days Inventory is 270.27, which is 62% above median its 10-year median of 167.21 and 47.6% above the Biotechnology industry median of 183.16. Titan Biotech's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Days Inventory is 270.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹427.80 is trading 193.9% above its estimated GF Value™ of ₹145.57.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Days Inventory: 270.27 (62% above median its 10-year median of 167.21)
GF Value™: ₹145.57 vs. price of ₹427.80 (193.9% above fair value)
Industry Position: 47.6% above the Biotechnology median (#337 of 637)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score
Get the complete analysis for BOM:524717
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
